# US 2010/0168872 A1 · Biomaterial scaffolds for controlled tissue growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168872 A1
- Document ID: US20100168872A1
- Status: Published application
- Kind: A1
- Application number: 12/676,342
- Filed: 2008-09-03
- Published: 2010-07-01
- Earliest claimed: 2007-09-04
- Assignees: UCL Business PLC
- Inventors: Robert BROWN; Tijna ALEKSEEVA
- Web page: https://patentgrep.com/patent/US20100168872A1

## CPC

- A61L 27/58: Materials at least partially resorbable by the body
- A61L 27/24: Collagen
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

This invention relates to biomaterials for directional tissue growth which comprise soluble fibres having a variable cross-sectional area which dissolve in a directional manner in situ, thereby controlling the direction and rate of formation of microchannels within the biomaterial and allowing vectored and timed channelling through the biomaterial. This may be useful, for example in directing the growth of blood vessels, nerves and other repair cells through the biomaterial in defined directions.

## Claims

### Claim 1

A biomaterial for directional tissue growth comprising;
a soluble fibre disposed within a scaffold,
the fibre having tissue entry and tissue exit ends,
wherein the cross-sectional area of the fibre progressively increasing from its entry end to its exit end such that the soluble fibre dissolves progressively from the entry end to the exit end,
the progressive dissolution of the fibre creating a microchannel within the scaffold for directional tissue growth from the entry end to the exit end of the fibre.

### Claim 2 (depends on 1)

A biomaterial according to claim 1 wherein the tissue entry end of the soluble fibre is disposed at a tissue entry end of the scaffold.

### Claim 3 (depends on 1, 2)

A biomaterial according to claim 1 or claim 2 wherein the tissue exit end of the soluble fibre is disposed at a tissue exit end of the scaffold.

### Claim 4 (depends on 3)

A biomaterial according to claim 3 wherein the soluble fibre connects the tissue entry and tissue exit ends of the scaffold and progressive dissolution of the fibre creates a microchannel for directional tissue growth from the entry end to the exit end of the scaffold.

### Claim 5

A biomaterial according to any one of the preceding claims wherein the scaffold is a gel.

### Claim 6 (depends on 5)

A biomaterial according to claim 5 wherein the gel is a collagen gel.

### Claim 7

A biomaterial according to any one of the preceding claims wherein the soluble fibre is composed of a single filament.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A biomaterial according to any one of claims 1 to 6 wherein the soluble fibre is composed of bundle of fibrils.

### Claim 9

A biomaterial according to any one of the preceding claims wherein the soluble fibre is a phosphate glass fibre.

### Claim 10

A biomaterial according to any one of the preceding claims wherein the cross-sectional area of the soluble fibre increases continuously from the entry end to the exit end of the scaffold.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A biomaterial according to any one of claims 1 to 9 wherein the cross-sectional area of the soluble fibre increases in steps from the entry end to the exit end of the scaffold.

### Claim 12

A biomaterial according to any one of the preceding claims comprising at least five soluble fibres within the scaffold.

### Claim 13

A biomaterial according to any one of the preceding claims wherein soluble fibres represent up to 50% of the total cross sectional area of the scaffold.

### Claim 14

A biomaterial according to any one of the preceding claims wherein the scaffold has undergone plastic compaction.

### Claim 15 (depends on 14)

A biomaterial according to claim 14 wherein the scaffold has undergone repeated cycles of uniaxial tensile loading following said compaction.

### Claim 16

A biomaterial according to any one of the preceding claims wherein the scaffold is seeded with viable cells before plastic compaction.

### Claim 17 (depends on 16)

A biomaterial according to claim 16 wherein the viable cells are selected from the group consisting of muscle cells, liver cells, kidney cells, heart cells, lung cells, gut cells, bronchial cells, ocular cells, reproductive cells, vascular cells, neural cells, secretory cells, stem cells, fibroblasts, Schwann cells, smooth muscle cells, endothelial cells, urothelial cells, osteocytes, chondrocytes, and tendon cells.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method of making a biomaterial according to any one of claims 1 to 17 comprising;
incorporating a soluble fibre into a scaffold,
the soluble fibre having a cross-sectional area which progressively increases from an entry end to an exit end of the fibre such that the fibre dissolves progressively from the entry end to the exit end,
the progressive dissolution of the fibre creating a microchannel in the scaffold for directional tissue growth though the scaffold from the entry end to the exit end of the fibre.

### Claim 19 (depends on 18)

A method according to claim 18 wherein the soluble fibre is produced by a method comprising:
providing a soluble fibre having a uniform cross-section along its length,
exposing the fibre to a solvent which dissolves the fibre,
removing the fibre from the solvent progressively from the second end to the first end,
thereby producing a fibre having a cross-sectional area which progressively increases from a first end to a second end.

### Claim 20 (depends on 18)

A method according to claim 18 wherein the soluble fibre is produced by assembling a plurality of soluble fibrils into a bundle.

### Claim 21 (depends on 18, 19, 20)

A method according to any one of claims 18 to 20 comprising implanting the biomaterial in a human or animal body for the repair or replacement of damaged tissue.

### Claim 22 (depends on 18, 19, 20)

A method according to any one of claims 18 to 20 comprising moulding or shaping the biomaterial to produce a tissue equivalent implant.

### Claim 23 (depends on 22)

A method according to claim 22 comprising folding or rolling the biomaterial to produce the implant.

### Claim 24 (depends on 22, 23)

A method according to claim 22 or claim 23 wherein the biomaterial is subjected to further plastic compaction to produce the implant.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A tissue equivalent implant comprising a biomaterial according to any one of claims 1 to 17.

### Claim 26 (depends on 25)

A method of treatment of a damaged tissue in an individual comprising;
fixing a tissue equivalent implant according to claim 25 to said damaged tissue to repair and/or replace said tissue.

### Claim 27 (depends on 25)

A tissue equivalent implant according to claim 25 for use in a method of treatment of a damaged tissue in an individual.

### Claim 28 (depends on 25)

Use of a tissue equivalent implant according to claim 25 in the manufacture of a medicament for use in the treatment of damaged tissue.

### Claim 29 (depends on 26, 27, 28)

A method according to claim 26, an implant according to claim 27 or a use according to claim 28 wherein the damaged tissue results from arthritides, neuro-muscle injury/degeneration, musculo-tendenous failure and age-degeneration, poor regeneration after trauma, tissue necrosis or surgical resection.
